Cancer

Dr. Michelle (Shelley) Barton’s remarkable career in cancer research, leadership, and graduate education is a testament to resilience, innovation, and an unwavering commitment to scientific advancement. As a researcher, she played a pivotal role in the discovery of TRIM24, a protein found in...

The School of Molecular & Cellular Biology and Department of Biochemistry are pleased to welcome Dr. Diana Ranoa as assistant professor of biochemistry. Dr. Ranoa...

Researchers at the University of Illinois Urbana-Champaign will develop a radically new platform to manufacture tumor models and expand their availability for medical research and personalized medicine, thanks to a $21 million grant from the Advanced Research Projects...

An interdisciplinary team of researchers from the University of Illinois has discovered a potential new treatment option for drug-resistant breast cancer. Their findings, published in Breast Cancer Research and Treatment,...

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75 percent of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these...

CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer, a type of aggressive, solid-tumor...

Scientists have identified a protein that plays a pivotal role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers.

Through a new approach of cross-linking cell proteins directly to a protein of interest, researchers at the University of Illinois Urbana-Champaign’s School of Molecular & Cellular Biology have distinguished new patterns of cell interactions with a molecular chaperone.  

Researchers from the School of Molecular & Cellular Biology at the University of Illinois Urbana-Champaign and the University of Illinois Chicago collaborated to highlight lipid-protein interaction as a new avenue for oncology drug development.

CHAMPAIGN, Ill. — Less than 20% of diagnosed breast cancers are designated “triple-negative,” meaning that the affected tissues lack three types of receptors often found in other breast cancer types, but TNBCs are often aggressive with ...